Lorusso Felice, Tartaglia Gianluca, Inchingolo Francesco, Scarano Antonio
Department of Innovative Technologies in Medicine and Dentistry, University of Chieti-Pescara, 66100 Chieti, Italy.
Department of Biomedical, Surgical and Dental Sciences, School of Dentistry, University of Milan, 20122 Milan, Italy.
Dent J (Basel). 2022 Jun 7;10(6):101. doi: 10.3390/dj10060101.
Polyvinylpyrrolidone/vinyl acetate (PVP/VA) is a molecule with increased adhesion capacity, and can be associated in the bacterial plaque control with sodium DNA, a natural anti-aging molecule able to improve gingival trophism. The aim of the study is to test at two weeks the antimicrobial and antiplaque properties, subjects affected by chronic periodontitis, showed by a mouthwash containing Chlorhexidine (CHX) 0.2% with Anti Discoloration System (ADS), PVP-VA, and Sodium DNA in comparison with a placebo mouthwash. A single center randomized controlled trial was conducted on a total of fifty-four (54) subjects. In the test Group (n = 27) patients were treated by a 0.2% Chlorhexidine (CHX) mouthwash with ADS, PVP-VA, and Sodium DNA, while a placebo mouthwash was used in the control Group (B). The full mouth plaque score (FMPS), full mouth bleeding score (FMBS), and gingival index (GI) were assessed at baseline, and at 1 and 2 weeks after treatment. FMPS score recorded at baseline (V2) was 52.7 ± 9.2 in the Group Test and 58.2 ± 6.1 in the Group Control (p > 0.05). After 1 week (V3), FMPS was 13.3 ± 5.6 in the Group Test and 18.7 ± 4.3 in the Group Control (p < 0.05), while at V4 (2 weeks), FMPS was 14.2 ± 4.1 in the Group Test and 20.3 ± 5.2 in the Group Control (p < 0.05). FMBS score recorded at baseline (V2) was 46.7 ± 8.7 in the Group Test and 49.2 ± 6.2 in the Group Control (p > 0.05). After 1 week (V3), FMBS was 12.7 ± 4.2 in the test Group Test and 18.5 ± 5.9 in the control Group Control (p < 0.05), while after 2 weeks (V4), it was 13.1 ± 3.2 in the Group Test and 19.8 ± 4.9 Group Control (p < 0.05). This trial has clinically showed the efficacy of a new formulation of chlorhexidine mouthwash in reducing bacterial plaque and gingival inflammation. A significant reduction of inflammation and bleeding scores was found in periodontal patients treated by a mouthwash containing CHX 0.2% with ADS, PVP-VA, and Sodium DNA compared to those treated with a placebo mouthwash.
聚乙烯吡咯烷酮/醋酸乙烯酯（PVP/VA）是一种具有增强粘附能力的分子，并且在控制细菌菌斑方面可与脱氧核糖核酸钠联合使用，脱氧核糖核酸钠是一种能够改善牙龈营养状况的天然抗老化分子。本研究的目的是在两周时测试一种含0.2%氯己定（CHX）并带有抗变色系统（ADS）、PVP-VA和脱氧核糖核酸钠的漱口水对慢性牙周炎患者的抗菌和抗牙菌斑特性，并与安慰剂漱口水进行比较。在总共五十四（54）名受试者中进行了一项单中心随机对照试验。在试验组（n = 27）中，患者使用含ADS、PVP-VA和脱氧核糖核酸钠的0.2%氯己定（CHX）漱口水进行治疗，而在对照组（B）中使用安慰剂漱口水。在基线以及治疗后1周和2周时评估全口菌斑评分（FMPS）、全口出血评分（FMBS）和牙龈指数（GI）。试验组在基线（V2）时记录的FMPS评分为52.7±9.2，对照组为58.2±6.1（p>0.05）。1周后（V3），试验组的FMPS为13.3±5.6，对照组为18.7±4.3（p<0.05），而在V4（2周）时，试验组的FMPS为14.2±4.1，对照组为20.3±5.2（p<0.05）。试验组在基线（V2）时记录的FMBS评分为46.7±8.7，对照组为49.2±6.2（p>0.05）。1周后（V3），试验组的FMBS为12.7±4.2，对照组为18.5±5.9（p<0.05），而2周后（V4），试验组为13.1±3.2，对照组为19.8±4.9（p<0.05）。该试验在临床上显示了一种新配方的氯己定漱口水在减少细菌菌斑和牙龈炎症方面的疗效。与使用安慰剂漱口水治疗的牙周炎患者相比，使用含0.2%CHX并带有ADS、PVP-VA和脱氧核糖核酸钠的漱口水治疗的牙周炎患者炎症和出血评分显著降低。
